Clinical Trial Update: A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing dasatinib to high-dose imatinib in chronic phase CML patients who failed to achieve complete cytogenetic response was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2009-09-03